Ceretec
Technetium Tc-99m Exametazime
Medi-physics Inc. Dba Ge Healthcare.
Human Prescription Drug
NDC 17156-022Ceretec also known as Technetium Tc-99m Exametazime is a human prescription drug labeled by 'Medi-physics Inc. Dba Ge Healthcare.'. National Drug Code (NDC) number for Ceretec is 17156-022. This drug is available in dosage form of Injection, Powder, Lyophilized, For Solution. The names of the active, medicinal ingredients in Ceretec drug includes Technetium Tc-99m Exametazime - .5 mg/5mL . The currest status of Ceretec drug is Active.
Drug Information:
| Drug NDC: | 17156-022 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Ceretec |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Prescription Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Technetium Tc-99m Exametazime |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Medi-physics Inc. Dba Ge Healthcare. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Injection, Powder, Lyophilized, For Solution |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | TECHNETIUM TC-99M EXAMETAZIME - .5 mg/5mL
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | INTRAVENOUS
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | NDA |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 30 Dec, 1988 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 22 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | NDA019829 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Medi-Physics Inc. dba GE Healthcare.
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| NUI: | N0000177914
N0000000205
|
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). |
| UNII: | 3B744AG22N
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
| Pharmacologic Class MOA: | Radiopharmaceutical Activity [MoA]
|
| Mechanism of action of the drug—molecular, subcellular, or cellular functional activity—of the drug’s established pharmacologic class. Takes the form of the mechanism of action, followed by `[MoA]` (such as `Calcium Channel Antagonists [MoA]` or `Tumor Necrosis Factor Receptor Blocking Activity [MoA]`. |
| Pharmacologic Class EPC: | Radioactive Diagnostic Agent [EPC]
|
| Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`. |
| Pharmacologic Class: | Radioactive Diagnostic Agent [EPC]
Radiopharmaceutical Activity [MoA]
|
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 17156-022-05 | 5 VIAL in 1 TRAY (17156-022-05) / 5 mL in 1 VIAL | 30 Dec, 1988 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Product Elements:
Ceretec technetium tc-99m exametazime technetium tc-99m exametazime technetium tc-99m exametazime exametazime stannous chloride sodium chloride nitrogen
Indications and Usage:
Indications and usage technetium tc99m exametazime scintigraphy may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke. tc99m exametazime is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease.
General Precautions:
General the contents of the ceretec vial are sterile and pyrogen free. the vial contains no bacteriostatic preservative. it is essential that the user follow the directions carefully and adhere to strict aseptic procedures during preparation of the radiopharmaceutical. radiopharmaceuticals should be used only by or under the control of physicians who are qualified by training and experience in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides. to minimize radiation dose to the bladder, the patient should be encouraged to void when the examination is completed and as often thereafter as possible. adequate hydration should be encouraged to permit frequent voiding.
Dosage and Administration:
Dosage and administration tc99m labeled leukocytes for adjunctive localization of intra-abdominal infection or inflammation. the normal adult (70 kg) dose is 0.259-0.925 gbq (7-25 mci) as tc99m labeled leukocytes by intravenous injection. optimal planar imaging is between 2-4 hours. cerebral scintigraphy the recommended dose range for i.v. administration, of reconstituted sodium pertechnetate tc99m exametazime in the average adult (70 kg) is 370-740 mbq (10-20 mci). dynamic imaging may be performed between 0 to 10 minutes following injection. static imaging may be performed from 15 minutes up to 6 hours after injection.
Contraindications:
Contraindications none known.
Adverse Reactions:
Adverse reactions rash with generalized erythema, facial edema and fever has been reported in less than 1% of patients. a transient increase in blood pressure was seen in 8% of patients.
Use in Pregnancy:
Pregnancy category c animal reproduction studies have not been conducted with tc99m exametazime. it is also not known whether tc99m exametazime can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity. therefore, tc99m exametazime should not be administered to a pregnant woman unless the potential benefit justifies the potential risk to the fetus.
Pediatric Use:
Pediatric use safety and effectiveness in pediatric patients have not been established.
Geriatric Use:
Geriatric use clinical studies of ceretec⢠did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Description:
Description the ceretec kit is supplied as a pack of 5 vials for use in the preparation of a technetium tc99m exametazime intravenous injection as a diagnostic radiopharmaceutical for use as an adjunct in the detection of altered regional cerebral perfusion and for the radiolabeling of autologous leukocytes. each vial of ceretec contains a pre-dispensed sterile, non-pyrogenic, lyophilized mixture of 0.5 mg exametazime [(rr,ss)-4.8-diaza-3,6,6,9-tetramethylundecane-2, 10-dione bisoxime], 7.6 µg stannous chloride dihydrate (minimum stannous tin 0.6 µg; maximum total stannous and stannic tin 4.0 µg per vial) and 4.5 mg sodium chloride, sealed under nitrogen atmosphere with a rubber closure. the product contains no antimicrobial preservative. prior to publication of the usan, exametazime was formerly known as hexamethylpropylene amine oxime (hm-pao). the name hm-pao appears in many publications. the structural formula of exametazime is: when sterile pyrogen-free sodium pertechnetate tc99m in isotonic saline is added to the vial of ceretec, a tc99m complex of exametazime is formed. administration is by intravenous injection for diagnostic use. physical characteristics technetium tc99m decays by isomeric transition with a physical half-life of 6.03 hours. (1) photons that are useful for imaging studies are listed in table 1. table 1. principal radiation emission data-technetium tc99m radiation mean %/ disintegration mean energy (kev) (1) dillman, l.t. and von der lage, f.c. radionuclide decay schemes and nuclear parameters for use in radiation-dose estimation. mird phamphlet no. 10, p. 62, 1975. gamma 2 87.87 140.5 external radiation the specific gamma ray constant for technetium tc99m is 206 microcoulomb kg-1/37 mbq-h, (0.8 r/millicurie-h) at 1 cm. the first half-value thickness of lead (pb) for technetium tc99m is 0.2 mm. a range of values for the relative attenuation of the radiation emitted by this radionuclide that results from interposition of various thicknesses of pb is shown in table 2. for example, the use of a 2.7 mm thickness of pb will decrease the external radiation exposure by a factor of 1,000. table 2. radiation attenuation by lead shielding shield thickness (pb) mm coefficient of attenuation 0.2 0.5 0.95 10 â1 1.8 10 â2 2.7 10 â3 3.6 10 â4 4.5 10 â5 to correct for physical decay of this radionuclide, the fractions that remain at selected intervals relative to the time of calibration are shown in table 3. table 3. physical decay chart: tc99m half-life 6.03 hours hours fraction remaining hours fraction remaining 0 calibration time (time of preparation) 1.000 7 0.447 1 0.891 8 0.399 2 0.795 9 0.355 3 0.708 10 0.317 4 0.631 11 0.282 5 0.563 12 0.252 6 0.502 24 0.063 chemical structure
Clinical Pharmacology:
Clinical pharmacology general when technetium tc99m pertechnetate is added to exametazime in the presence of stannous reductant, a lipophilic technetium tc99m complex is formed. this lipophilic complex is the active moiety. it converts at approximately 12%/hour to less lipophilic species. when the secondary complex is separated from the lipophilic species, it is unable to cross the blood-brain-barrier. the useful life of the reconstituted agent is limited to 30 minutes. pharmacokinetics studies in normal volunteers have shown that the technetium tc99m complex of the rr,ss(d,l) diastereoisomer of exametazime is rapidly cleared from the blood after intravenous injection. uptake in the brain reaches a maximum of 3.5-7.0% of the injected dose within one minute of injection. up to 15% of the activity is eliminated from the brain by 2 minutes post injection, after which little activity is lost for the following 24 hours except by physical decay of technetium tc99m. the activity not associate
Read more...d with the brain is widely distributed throughout the body, particularly in muscle and soft tissue. about 30% of the injected dose is found in the gastrointestinal tract immediately after injection and about 50% of this is excreted through the intestinal tract over 48 hours. also, about 40% of the injected dose is excreted through the kidneys and urine over the 48 hours after injection. leukocyte the lipophilic tc99m exametazime complex is taken up by leukocytes, and selectively retained in neutrophils. label elution rate is up to 10% in the first hour. pharmacodynamics tc99m-labeled leukocyte: based upon in vivo recovery and very low lung and liver uptake, the labeled leukocytes are still functional. following reinjection of the tc99m labeled leukocytes the circulating granulocyte activity as a percentage of labeled granulocyte activity at 40 minutes after injection gave a mean of 37% (range 10-47%). during the first hour following injection of tc99m labeled leukocytes, activity is seen in the lungs, liver, spleen, blood pool, bone marrow and the bladder. the kidneys (parenchyma and/or renal pelvis) and gall bladder may also be visualized. over the first 1-6 hours, the tc99m is visualized in the bowel. at 24 hours post-injection substantial colonic activity is seen. the normal areas visualized in earlier scans are still visible.
Carcinogenesis and Mutagenesis and Impairment of Fertility:
Carcinogenesis, mutagenesis, impairment of fertility long term animal studies have not been performed to evaluate carcinogenic potential or whether exametazime affects fertility in males or females. when evaluated in the ames test, exametazime increased the apparent rate of gene mutation in the ta100 strain of s. typhimurium. exametazime did not cause chromosomal aberrations in vitro (chinese hamster ovary cells) or in vivo (rat bone marrow).
Clinical Studies:
Clinical trials two clinical trials were performed in a total of 88 patients who had suspected intra-abdominal infection or inflammation. subjects received both tc99m labeled leukocytes and in-111 labeled leukocytes. images were obtained at 2 and 30 minutes and at 2 and 4 hours and 24 hours. in two other clinical trials, in a total of 127 patients with suspected abdominal inflammation or infection received tc99m labeled leukocytes. imaging was at 24 hours in one study and at 1, 3 and 24 hours in the other. in all 4 studies, images were blindly evaluated and the findings were confirmed by surgery, biopsy or other clinical data. based on the above 4 studies, between 2 to 4 hours tc99m labeled leukocytes had 95-100% sensitivity and 62-85% specificity with similar numbers of false positive and false negative findings. the value of the 24 hour tc99m labeled leukocyte images is inconsistent. in all studies the false positive and false negatives relate to the bowel background, the location of
Read more... the site of infection/inflammation and whether or not it is contiguous with the bowel. the 24 hour films should be interpreted with great caution because of a high bowel background; false negatives were noted in both tc99m and in-111 labeled leukocytes. other studies suggest that the interpretation of the images could be affected by the presence of tumors, infarction and peritonitis, etc. liver abscess may be missed because of the bowel background. caution should be exercised in making the final diagnosis.
How Supplied:
How supplied the kit comprises 5 individual vials of sterile, non-pyrogenic, freeze-dried mixture of exametazime, stannous chloride dihydrate and sodium chloride, 5 radiation labels, 5 radiochemical purity worksheets, 5 labeling efficiency worksheets, 1 leukocyte labeling schematic and 1 package insert. ndc 17156-022-05 storage store the kit at 15°-25°c (59°-77°f). store the formulated drug for up to 30 minutes at 20°-25°c (68°-77°f) using appropriate radiation shielding. this reagent kit is approved for use by persons licensed by the illinois emergency management agency pursuant to 32 ill. code adm. section, section 330.260(a) and 335.4010 or under equivalent licenses of the u.s. nuclear regulatory commission, or an agreement state.
Package Label Principal Display Panel:
Principal display panel - 5 vial kit ge healthcare ceretec⢠technetium tc99m exametazime injection code n109 5-vial kit ndc 17156-022-05 storage: store the kit at 15°-25°c (59°-77°f). after reconstitution with technetium tc99m, store at 20°-25°c (68°-77°f). use appropriate radiation shielding. not for use in humans until technetium tc99m is added. for intravenous use as directed. for dosage and administration: see package insert. content. each package contains the following: five ceretec vials. each ceretec vial contains a lyophilized form of 0.5 mg exametazime. 7.6 μg, stannous chloride dihydrate (minimum stannous tin 0.6 μg, maximum total stannous and stannic tin 4.0 μg per vial) and 4.5 mg sodium chloride. for preparation of technetium tc99m exametazime injection see package insert. 44p-9159f-oslo principal display panel - 5 vial kit